Literature DB >> 12421830

Sp1 transactivation of the TCL1 oncogene.

Samuel W French1, Cindy S Malone, Rhine R Shen, Mathilde Renard, Sarah E Henson, Maurine D Miner, Randolph Wall, Michael A Teitell.   

Abstract

Cis-regions and trans-factors controlling TCL1 oncogene expression are not known. We identified the functional TCL1 promoter by mapping four transcriptional start sites 24-30 bp downstream of a TATA box. A 424-bp fragment upstream of the major start site showed robust promoter activity comparable with SV40 in both TCL1 expressing and non-expressing cell lines. Additional constructs spanning 10 kb upstream and 20 kb downstream of the start site showed only modest increases in reporter activity indicating that TCL1 expression is primarily controlled by the promoter. Ten putative Sp1-binding sites were identified within 300 bp of the start site, and three of these specifically bound Sp1. A dose-dependent transactivation of the TCL1 promoter with Sp1 addition in Sp1-negative Drosophila SL2 cells was observed, and mutation of the three identified Sp1-binding sites significantly repressed reporter gene expression in 293T cells, confirming a key role for Sp1 in activating the TCL1 promoter in vivo. In TCL1 silent cell lines, CpG DNA methylation was rarely observed at functional Sp1 sites, and methylation of a previously reported NotI restriction site was associated with dense CpG methylation rather than endogenous TCL1 gene silencing. Together, these results indicate that Sp1 mediates transactivation of the TCL1 core promoter and that TCL1 gene silencing is not dependent on mechanisms involving Sp1 and NotI site methylation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421830     DOI: 10.1074/jbc.M207166200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation.

Authors:  Ali I Kuraishy; Samuel W French; Mara Sherman; Marco Herling; Dan Jones; Randolph Wall; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

2.  Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages.

Authors:  Uma K Misra; Steven J Kaczowka; Salvatore V Pizzo
Journal:  Cell Signal       Date:  2007-10-12       Impact factor: 4.315

3.  Changes in transcriptional factor binding capacity resulting from promoter region methylation induce aberrantly high GDNF expression in human glioma.

Authors:  Zheng-Quan Yu; Bao-Le Zhang; Qing-Xian Ren; Jian-Cun Wang; Ru-Tong Yu; De-Wei Qu; Ze-Hao Liu; Ye Xiong; Dian-Shuai Gao
Journal:  Mol Neurobiol       Date:  2013-04-19       Impact factor: 5.590

4.  Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-Associated B-lymphoma cells and contributes to their proliferation.

Authors:  Jie Lu; Subhash C Verma; Masanao Murakami; Qiliang Cai; Pankaj Kumar; Bingyi Xiao; Erle S Robertson
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

5.  Maximal Expression of the Evolutionarily Conserved Slit2 Gene Promoter Requires Sp1.

Authors:  Jacquelyn Saunders; D Roonalika Wisidagama; Travis Morford; Cindy S Malone
Journal:  Cell Mol Neurobiol       Date:  2015-10-11       Impact factor: 5.046

6.  Functional role of post-translational modifications of Sp1 in tumorigenesis.

Authors:  Wen-Chang Chang; Jan-Jong Hung
Journal:  J Biomed Sci       Date:  2012-11-14       Impact factor: 8.410

7.  T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways.

Authors:  Francesco Paduano; Eugenio Gaudio; Afua A Mensah; Sandra Pinton; Francesco Bertoni; Francesco Trapasso
Journal:  Front Oncol       Date:  2018-08-13       Impact factor: 6.244

Review 8.  Interaction of microRNAs with sphingosine kinases, sphingosine-1 phosphate, and sphingosine-1 phosphate receptors in cancer.

Authors:  Guangmeng Xu; Zecheng Yang; Yamin Sun; Hongmei Dong; Jingru Ma
Journal:  Discov Oncol       Date:  2021-09-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.